Table 2 Comparison of pulmonary function test results between the two main visits
From: The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement
Baseline visit (V1) | Follow-up visit (V2) | Mean difference | p-valuea | ||
|---|---|---|---|---|---|
(mean ± SD) | (mean ± SD) | MD ± SD | |||
CS group ( N = 131) | VC [L, ml] | 3.25 ± 0.86 | 3.65 ± 0.89 | 403.7 ± 510.05 | 0,0003 |
VC [%predicted] | 86.93 ± 17.25 | 97.22 ± 14.96 | 10.29 ± 13.33 | <0.0001 | |
FEV1/VC [%] | 79.96 ± 7.75 | 79.04 ± 7.69 | -0.92 ± 5.23 | 0,3299 | |
TLC [L, ml] | 5.68 ± 1.21 | 6.30 ± 1.25 | 649.84 ± 756.45 | 0,0001 | |
TLC [%predicted] | 90.78 ± 16.36 | 100.09 ± 14.86 | 9.95 ± 12.16 | <0.0001 | |
RV [L, ml] | 2.48 ± 0.72 | 2.67 ± 0.71 | 204.69 ± 700.12 | 0,0366 | |
RV [%predicted] | 108.24 ± 28.88 | 115.32 ± 27.35 | 8.37 ± 29.19 | 0,0299 | |
DLCOc [%predicted] | 57.69 ± 15.94 | 66.90 ± 14.93 | 10.18 ± 12.55 | <0.0001 | |
KCOc [%predicted] | 79.31 ± 16.00 | 83.13 ± 16.51 | 4.43 ± 11.85 | 0,0969 | |
WW group ( N = 894 b ) | VC [L, ml] | 3.56 ± 0.98 | 3.65 ± 0.99 | 95.1 ± 353.23 | 0,0336 |
VC [%predicted] | 99.23 ± 16.18 | 101.91 ± 15.65 | 2.68 ± 9.94 | 0,0006 | |
FEV1/VC [%] | 79.29 ± 7.00 | 78.56 ± 6.84 | -0.73 ± 4.71 | 0,0212 | |
TLC [L, ml] | 6.11 ± 1.30 | 6.20 ± 1.34 | 92.72 ± 758.67 | 0,2036 | |
TLC [%predicted] | 105.16 ± 15.72 | 106.31 ± 14.65 | 1.27 ± 12.84 | 0,1159 | |
RV [L, ml] | 2.61 ± 0.71 | 2.63 ± 0.71 | 22.18 ± 611.47 | 0,6972 | |
RV [%predicted] | 126.57 ± 30.38 | 126.59 ± 28.51 | 0.18 ± 29.61 | 0,8244 | |
DLCOc [%predicted] | 77.79 ± 15.96 | 80.11 ± 14.71 | 2.79 ± 12.82 | 0,0101 | |
KCOc [%predicted] | 88.48 ± 15.43 | 89.10 ± 15.14 | 1.51 ± 10.01 | 0,5088 | |